Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RMTI's Cash to Debt is ranked higher than
99% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RMTI' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 29.14 Max: No Debt
Current: No Debt
Equity to Asset 0.68
RMTI's Equity to Asset is ranked higher than
59% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RMTI: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
RMTI' s Equity to Asset Range Over the Past 10 Years
Min: -0.59  Med: 0.64 Max: 0.92
Current: 0.68
-0.59
0.92
Interest Coverage No Debt
RMTI's Interest Coverage is ranked higher than
98% of the 468 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.86 vs. RMTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RMTI' s Interest Coverage Range Over the Past 10 Years
Min: 0.69  Med: 9999.00 Max: N/A
Current: No Debt
F-Score: 4
Z-Score: 5.82
M-Score: -2.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -28.85
RMTI's Operating margin (%) is ranked lower than
84% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. RMTI: -28.85 )
Ranked among companies with meaningful Operating margin (%) only.
RMTI' s Operating margin (%) Range Over the Past 10 Years
Min: -108.87  Med: -15.92 Max: 0.49
Current: -28.85
-108.87
0.49
Net-margin (%) -28.22
RMTI's Net-margin (%) is ranked lower than
84% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. RMTI: -28.22 )
Ranked among companies with meaningful Net-margin (%) only.
RMTI' s Net-margin (%) Range Over the Past 10 Years
Min: -108.39  Med: -15.60 Max: 0.28
Current: -28.22
-108.39
0.28
ROE (%) -24.23
RMTI's ROE (%) is ranked lower than
81% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. RMTI: -24.23 )
Ranked among companies with meaningful ROE (%) only.
RMTI' s ROE (%) Range Over the Past 10 Years
Min: -1304.41  Med: -52.81 Max: 2.12
Current: -24.23
-1304.41
2.12
ROA (%) -17.03
RMTI's ROA (%) is ranked lower than
80% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. RMTI: -17.03 )
Ranked among companies with meaningful ROA (%) only.
RMTI' s ROA (%) Range Over the Past 10 Years
Min: -220.66  Med: -34.71 Max: 0.91
Current: -17.03
-220.66
0.91
ROC (Joel Greenblatt) (%) -232.67
RMTI's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. RMTI: -232.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RMTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2678.13  Med: -126.49 Max: 6.35
Current: -232.67
-2678.13
6.35
Revenue Growth (3Y)(%) -22.00
RMTI's Revenue Growth (3Y)(%) is ranked lower than
90% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. RMTI: -22.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RMTI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: 1.60 Max: 36.8
Current: -22
-22.9
36.8
EBITDA Growth (3Y)(%) -30.00
RMTI's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. RMTI: -30.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RMTI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.5  Med: -19.20 Max: 165.1
Current: -30
-36.5
165.1
EPS Growth (3Y)(%) -24.70
RMTI's EPS Growth (3Y)(%) is ranked lower than
84% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. RMTI: -24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RMTI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.30 Max: 111.4
Current: -24.7
0
111.4
» RMTI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

RMTI Guru Trades in Q1 2015

Paul Tudor Jones 25,170 sh (New)
» More
Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
Q3 2015

RMTI Guru Trades in Q3 2015

Paul Tudor Jones 49,916 sh (+91.73%)
» More
Q4 2015

RMTI Guru Trades in Q4 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:BITI, NAS:AERI, OTCPK:BGAIF, NAS:ZGNX, OTCPK:EUYNF, OTCPK:ULIHF, NAS:NBRV, OTCPK:ABSCF, NAS:OASM, NAS:RTRX, NAS:ASMB, OTCPK:MBGRF, OTCPK:SKYEY, AMEX:NNVC, OTCPK:BIOYF, NAS:ALIM, OTCPK:PMXSF, NAS:NTEC, AMEX:AXN, NAS:TNXP » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.

Ratios

vs
industry
vs
history
P/B 6.28
RMTI's P/B is ranked lower than
83% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. RMTI: 6.28 )
Ranked among companies with meaningful P/B only.
RMTI' s P/B Range Over the Past 10 Years
Min: 1.73  Med: 7.83 Max: 950
Current: 6.28
1.73
950
P/S 6.69
RMTI's P/S is ranked lower than
77% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. RMTI: 6.69 )
Ranked among companies with meaningful P/S only.
RMTI' s P/S Range Over the Past 10 Years
Min: 0.47  Med: 2.48 Max: 14.67
Current: 6.69
0.47
14.67
Current Ratio 10.71
RMTI's Current Ratio is ranked higher than
91% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. RMTI: 10.71 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.89 Max: 12.58
Current: 10.71
0.49
12.58
Quick Ratio 9.56
RMTI's Quick Ratio is ranked higher than
91% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. RMTI: 9.56 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.59 Max: 11.68
Current: 9.56
0.35
11.68
Days Inventory 56.13
RMTI's Days Inventory is ranked higher than
81% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. RMTI: 56.13 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s Days Inventory Range Over the Past 10 Years
Min: 21.46  Med: 23.36 Max: 33.28
Current: 56.13
21.46
33.28
Days Sales Outstanding 41.23
RMTI's Days Sales Outstanding is ranked higher than
79% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. RMTI: 41.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 32.18 Max: 44.28
Current: 41.23
23.3
44.28
Days Payable 34.49
RMTI's Days Payable is ranked lower than
82% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. RMTI: 34.49 )
Ranked among companies with meaningful Days Payable only.
RMTI' s Days Payable Range Over the Past 10 Years
Min: 26.41  Med: 40.18 Max: 125.48
Current: 34.49
26.41
125.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.28
RMTI's Price/Net Cash is ranked higher than
58% of the 211 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.34 vs. RMTI: 9.28 )
Ranked among companies with meaningful Price/Net Cash only.
RMTI' s Price/Net Cash Range Over the Past 10 Years
Min: 4.11  Med: 14.93 Max: 394
Current: 9.28
4.11
394
Price/Net Current Asset Value 6.67
RMTI's Price/Net Current Asset Value is ranked higher than
50% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.67 vs. RMTI: 6.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RMTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.27  Med: 10.47 Max: 315
Current: 6.67
3.27
315
Price/Tangible Book 6.39
RMTI's Price/Tangible Book is ranked lower than
74% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. RMTI: 6.39 )
Ranked among companies with meaningful Price/Tangible Book only.
RMTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.68  Med: 8.23 Max: 98.28
Current: 6.39
2.68
98.28
Price/Median PS Value 2.72
RMTI's Price/Median PS Value is ranked lower than
89% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. RMTI: 2.72 )
Ranked among companies with meaningful Price/Median PS Value only.
RMTI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 0.81 Max: 5.36
Current: 2.72
0.16
5.36
Earnings Yield (Greenblatt) (%) -4.90
RMTI's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RMTI: -4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RMTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 0.90 Max: 1.4
Current: -4.9
0.7
1.4

More Statistics

Revenue (TTM) (Mil) $55.10
EPS (TTM) $ -0.32
Beta2.60
Short Percentage of Float21.43%
52-Week Range $5.47 - 18.90
Shares Outstanding (Mil)51.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 57 73 85
EPS ($) -0.29 0.03 0.24
EPS w/o NRI ($) -0.29 0.03 0.24
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 23 2016
Rockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors Jun 23 2016
Rockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors Jun 23 2016
Rockwell Medical, Inc. – Value Analysis (NASDAQ:RMTI) : June 20, 2016 Jun 20 2016
Rockwell Medical, Inc. breached its 50 day moving average in a Bearish Manner : RMTI-US : June 14,... Jun 14 2016
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 06 2016
ETF’s with exposure to Rockwell Medical, Inc. : June 3, 2016 Jun 03 2016
ETF’s with exposure to Rockwell Medical, Inc. : May 19, 2016 May 19 2016
ROCKWELL MEDICAL, INC. Financials May 19 2016
Rockwell Medical, Inc. :RMTI-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2016
Rockwell Medical Announces Multiple International Trademark Approvals for Triferic® May 12 2016
Rockwell Medical Announces Multiple International Trademark Approvals for Triferic® May 12 2016
Edited Transcript of RMTI earnings conference call or presentation 10-May-16 8:30pm GMT May 10 2016
ROCKWELL MEDICAL, INC. Files SEC form 10-Q, Quarterly Report May 10 2016
Rockwell Medical reports 1Q loss May 10 2016
Rockwell Medical reports 1Q loss May 10 2016
Rockwell Medical Reports First Quarter Results May 10 2016
Rockwell Medical Reports First Quarter Results May 10 2016
Q1 2016 Rockwell Medical Inc Earnings Release - After Market Close May 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)